CivilsIASPrep.comStudy attempts to find out how India made expensive diabetes medicines affordable
What does this development mean for UPSC preparation?
A study in Diabetes Care examines how India made modern diabetes drugs affordable, offering lessons for other low- and middle-income countries.
UPSC CSE Context
Why in News
A study in Diabetes Care examines how India made modern diabetes drugs affordable, offering lessons for other low- and middle-income countries.
Syllabus Connection
GS Paper 2: Health, Government policies and interventions; GS Paper 3: Issues related to intellectual property rights, pharmaceutical sector.
Exam Relevance
Relevant for questions on public health, access to medicines, patent law, and India's pharmaceutical industry.
Core Issue
India's generic-friendly patent law and domestic manufacturing lowered diabetes drug prices.
Key Development
Study highlights India's success in reducing prices of GLP-1 RAs, SGLT2i, and analogue insulins through generic competition and policy measures.
Stakeholders
- Government of India
- Domestic pharmaceutical manufacturers
- Patients with diabetes
- Global trade bodies
Static Knowledge
High-Value Background
- India's Patents Act, 1970 (as amended) includes Section 3(d) to prevent evergreening, enabling generic production.
- National List of Essential Medicines (NLEM) includes metformin and sulfonylureas but not newer diabetes drugs.
Exam Linkage
- Useful for questions on compulsory licensing, TRIPS flexibilities, and access to medicines.
Concepts in Context
- Patent evergreening: extending patent life through minor modifications, blocked by Section 3(d).
- Generic drugs: bioequivalent versions of off-patent drugs, cheaper due to competition.
Institutions and Mechanisms
- Jan Aushadhi Kendras: government-run pharmacies selling affordable generic medicines.
- Production Linked Incentive (PLI) scheme for domestic API manufacturing.
Dynamic Analysis
Health Policy
- Affordability of newer diabetes drugs remains limited by high absolute costs relative to household income.
- Lack of insurance coverage for these drugs increases out-of-pocket expenditure.
- Urban-rural disparities in medicine distribution hinder equitable access.
- Government schemes like Jan Aushadhi Kendras improve access but need formal evaluation of long-term clinical outcomes.
Economy
- India's role as major pharma exporter supports low domestic prices through economies of scale.
- Competitive entry by multiple domestic manufacturers drastically reduced semaglutide prices.
- Dependence on imported raw materials poses supply chain risks; PLI scheme aims to boost domestic API production.
- Tight price regulation may discourage innovation and investment in R&D.
International Relations
- India's patent law balances TRIPS compliance with public health needs, serving as a model for LMICs.
- Global trade policies and intellectual property regimes can affect medicine prices and availability.
- India's experience offers lessons for other countries facing high drug prices, including high-income nations.
Governance
- Regulatory strategies like price caps and distribution networks are key to affordability.
- Pharmacovigilance challenges arise with multiple generic manufacturers and quality variations.
- Need for aligning pharmaceutical policy with health financing and monitoring systems.
Prelims Takeaways
- Section 3(d) of Indian Patents Act prevents patent evergreening.
- Jan Aushadhi Kendras provide affordable generic medicines.
Mains Value Addition
Arguments
- India's success in reducing diabetes drug prices demonstrates the effectiveness of generic competition and patent safeguards.
- However, high absolute costs and lack of insurance coverage limit true affordability for many patients.
- Balancing innovation incentives with access to medicines is a key policy challenge.
- Strengthening domestic API manufacturing reduces import dependence and enhances health security.
Examples
- Semaglutide price dropped considerably after multiple domestic manufacturers entered the market.
- PLI scheme has initiated production of 26 previously imported molecules as of 2025.
Data Points
- 80% of 589 million adults with diabetes live in LMICs.
- Metformin and sulfonylureas are in NLEM; DPP-4 inhibitors, SGLT2i, GLP-1 RAs are not.
Counterpoints
- Tight regulations may hinder drug innovation.
- Quality differences among generics pose safety concerns.
- Limited formal evaluation of government schemes' long-term impact.
Way Forward
- Include newer diabetes drugs in NLEM to enable price regulation and wider access.
- Expand insurance coverage for modern diabetes therapies to reduce out-of-pocket costs.
- Strengthen pharmacovigilance systems to ensure generic drug quality.
- Evaluate Jan Aushadhi Kendras and PLI scheme for long-term health outcomes.
- Promote technology transfer and local manufacturing in LMICs through international cooperation.